SCHEMBL3390707

SCHEMBL3390707

CC(=O)OCCCCCCCCCCCCC1=C(C)CCCC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 2/20 0.44
RARG P13631 2/20 0.44
RARA P10276 1/20 0.44
RXRA P19793 1/20 0.44
TRPA1 O75762 5/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ACE2 Q9BYF1 4/20 0.41
PDCD1 Q15116 3/20 0.41
CD274 Q9NZQ7 3/20 0.41
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
LMNA P02545 2/20 0.38
APOBEC3A P31941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15082362 0.81 RARB (0.49) RARBRARGRARARXRATRPA1
SCHEMBL25229798 0.81 ALDH1A1 (0.40) RARBRARGRARARXRATRPA1
SCHEMBL14157478 0.80 RARB (0.46) RARBRARGRARARXRATRPA1
SCHEMBL3391095 0.80 TRPA1 (0.43) TRPA1ALDH1A1MAPTLMNAAPOBEC3A
SCHEMBL14157557 0.78 RARB (0.49) RARBRARGRARARXRATRPA1
SCHEMBL29965248 0.77 ALDH1A1 (0.45) RARBRARGRARARXRATRPA1
SCHEMBL7185668 0.77 ALDH1A1 (0.45) RARBRARGRARARXRATRPA1
SCHEMBL9266425 0.77 ALDH1A1 (0.45) RARBRARGRARARXRATRPA1
SCHEMBL7017316 0.77 ALDH1A1 (0.45) RARBRARGRARARXRATRPA1
SCHEMBL31502598 0.75 TRPA1 (0.47) RARBRARGRARARXRATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1839653-B9 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
EP-2196200-A1 Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes Meiji Dairies Corporation (JP) 2010-06-16 EP disclosed
EP-1839653-B1 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-06-09 EP disclosed
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality MEIJI CO., LTD (JP) 2009-03-12 US disclosed
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder UNIVERSITE DE STRASBOURG (FR) 2008-12-18 US disclosed
EP-1839653-A1 THERAPEUTIC AGENT FOR SENSORY ABNORMALITY Meiji Dairies Corporation (JP) 2007-10-03 EP disclosed
US-7166642-B1 Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases MEIJI DAIRIES CORPORATION (JP) 2007-01-23 US disclosed
EP-1150667-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS MEIJI DAIRIES CORP (JP) 2004-07-14 EP disclosed
EP-1003706-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PROD CO LTD (JP) 2003-03-05 EP disclosed
US-6228893-B1 TREATING DEMENTIA MEIJI MILK PRODUCTS CO., LTD. (JP) 2001-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder CPT1B, CHRM1, ADRA1D RARB 1561/4885RARG 1605/4885RARA 1452/4885
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality PMP22, NGF, HRH1 RARB 3229/4885RARG 3767/4885RARA 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.